Siglec and anti-Siglec therapies
- PMID: 33607404
- DOI: 10.1016/j.cbpa.2021.01.001
Siglec and anti-Siglec therapies
Abstract
Siglecs (sialic acid-binding immunoglobulin-like lectins) are a family of receptors that bind sialic acids in specific linkages on glycoproteins and glycolipids. Siglecs play roles in immune signalling and exhibit cell-type specific expression and endocytic properties. Recent studies suggest that Siglecs are likely to function as immune checkpoints that regulate responses in cancers and inflammatory diseases. In this review, we discuss strategies to target the Siglec-sialic acid axis in human diseases, particularly cancer, and the possibility of exploiting them for therapeutic intervention.
Keywords: Cancer; Immune checkpoint; Inflammation; Sialic acid; Siglec.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest PRC is a scientific cofounder and Scientific Advisory Board member of Palleon Pharmaceuticals. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Sialic Acid-Siglec Axis in Human Immune Regulation, Involvement in Autoimmunity and Cancer and Potential Therapeutic Treatments.Int J Mol Sci. 2021 May 28;22(11):5774. doi: 10.3390/ijms22115774. Int J Mol Sci. 2021. PMID: 34071314 Free PMC article. Review.
-
Tools to study and target the Siglec-sialic acid axis in cancer.FEBS J. 2021 Nov;288(21):6206-6225. doi: 10.1111/febs.15647. Epub 2020 Dec 21. FEBS J. 2021. PMID: 33251699 Review.
-
Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.Glycobiology. 2018 Sep 1;28(9):640-647. doi: 10.1093/glycob/cwx108. Glycobiology. 2018. PMID: 29309569 Review.
-
Modulation of Immune Tolerance via Siglec-Sialic Acid Interactions.Front Immunol. 2018 Dec 7;9:2807. doi: 10.3389/fimmu.2018.02807. eCollection 2018. Front Immunol. 2018. PMID: 30581432 Free PMC article. Review.
-
The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.Expert Opin Ther Targets. 2019 Oct;23(10):839-853. doi: 10.1080/14728222.2019.1667977. Epub 2019 Sep 23. Expert Opin Ther Targets. 2019. PMID: 31524529 Review.
Cited by
-
Targeting the Siglec-Sialic Acid Immune Axis in Cancer: Current and Future Approaches.Cancer Immunol Res. 2022 Dec 2;10(12):1423-1432. doi: 10.1158/2326-6066.CIR-22-0366. Cancer Immunol Res. 2022. PMID: 36264237 Free PMC article. Review.
-
Differential expression of ST6GALNAC1 and ST6GALNAC2 and their clinical relevance to colorectal cancer progression.PLoS One. 2024 Sep 30;19(9):e0311212. doi: 10.1371/journal.pone.0311212. eCollection 2024. PLoS One. 2024. PMID: 39348343 Free PMC article.
-
Siglec Signaling in the Tumor Microenvironment.Front Immunol. 2021 Dec 13;12:790317. doi: 10.3389/fimmu.2021.790317. eCollection 2021. Front Immunol. 2021. PMID: 34966391 Free PMC article. Review.
-
Sialic Acid-Modified Nanoparticles-New Approaches in the Glioma Management-Perspective Review.Int J Mol Sci. 2021 Jul 13;22(14):7494. doi: 10.3390/ijms22147494. Int J Mol Sci. 2021. PMID: 34299113 Free PMC article. Review.
-
Glycosylation Targeting: A Paradigm Shift in Cancer Immunotherapy.Int J Biol Sci. 2024 Apr 22;20(7):2607-2621. doi: 10.7150/ijbs.93806. eCollection 2024. Int J Biol Sci. 2024. PMID: 38725856 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical